Synthesis of OJSC Kurgan Society of Medical Products and Products

Joint-stock Kurgan Company of Medical Products and Products Sintez (OJSC) is one of the enterprises of the pharmaceutical industry in Russia. The company has been producing medicines since 1958. As of April 2017, in terms of production volumes, the plant is one of the ten leaders in the domestic pharmaceutical industry, providing about 3% of the Russian production of medicines.

Performance indicators

2020

Revenue growth by 42% to more than 13 billion rubles

On April 2, 2021 pharmaceutical , the holding Binnopharm Group"," combining portfolio companies - AFK Sistema JSC "" Alium(includes JSC "") and Binnopharm OJSC "Synthesis" (includes CJSC Biolump""), shared with Zdrav.Expert financial the results of OJSC "Synthesis" under RAS for 2020.

The revenue of the Kurgan enterprise increased by 42% year-on-year and exceeded 13 billion rubles. In 2020, Sintez produced 317 million packages of finished products.

{{quote 'author = said CEO of Binnopharm Rustem Muratov Group Pandemic.|made adjustments to the production plans of all plants of Binnopharm Group, had to quickly and flexibly respond to market needs and changes in demand. At the site in Kurgan, according to the results of 2020, we increased by 44% the production of drugs Ministry of Health of Russia that were recommended to be used treatment of COVID-19 in protocols - mainly these antibiotics, which are used in especially severe cases of the course of the disease. At the same time, we not only did not reduce the production of other demanded drugs that are not related to, COVID-19 but also increased in many positions. Production facilities of "Synthesis" in 2020 were loaded to the maximum, }}

The volume of sales of "Synthesis" in 2020 in the retail segment increased by 25%, the leaders in retail were analgesics "Diclofenak-AKOS" and "Ibuprofen-AKOS," antibiotics "Ceftriaxone" and "Levofloxacin," as well as nasal spray decongestant "Rhinorus."

According to the results of 2020, revenue from the sale of the company's export products increased by 40% in monetary terms and exceeded 2 billion rubles. The largest volumes of Synthesis products were delivered to Uzbekistan, Kazakhstan and Turkmenistan.

At the end of October 2020, Sintez and 4 more production sites of Alium JSC (Serpukhov district of the Moscow region), Binnopharm JSC (2 sites: Zelenograd and Krasnogorsk) and Biokom CJSC ( Stavropol) became part of the Binnopharm Group holding, which unites portfolio companies of AFK Sistema.

Profit growth for 9 months by 45% to 1.145 billion rubles

On November 13, 2020, Sintez OJSC (part of the Binnopharm Group holding) published its financial statements under RAS for 9 months of 2020. The company's revenue increased by 42% compared to the same period in 2019 and amounted to 10.362 billion rubles. Net profit increased by 45% year-on-year to 1.145 billion rubles.

For "Synthesis," the third quarter turned out to be very tense. The production sites were loaded and worked in three shifts to ensure the increased requests of medical institutions and retail due to the pandemic. We had to quickly increase the production of antibiotics by an average of 30%, "says Rustem Muratov, General Director of Binnopharm Group. - We supply products both to the hospital market and to pharmacies through distributors.

At the end of 9 months of 2020, sales of Synthesis OJSC in the hospital segment almost doubled in monetary terms, and 29% increased in the retail segment. The sales leaders were the over-the-counter analgesics Diclofenac and Ibuprofen, as well as the antibiotic Ceftriaxone, which is available on a doctor's prescription.

OJSC Sintez annually produces about 300 million packages of medicines.

Revenue growth for the first half of the year by 42% to 6.767 billion rubles

On August 14, 2020, Sintez OJSC (part of Alium Group) disclosed its financial results under RAS for 6 months of 2020. The company's revenue increased by 42% year-on-year to 6.767 billion rubles.

Net profit reached 752.9 million rubles, which is 23% more than in the same period in 2019. Export sales grew by 36% year-on-year, exceeding 1 billion rubles.

"The first half of 2020 was very tense for enterprises in the pharmaceutical industry in connection with the coronavirus pandemic. But we were able to quickly increase the production of the drugs necessary for the country's medical institutions - there are 14 INNs in the Synthesis portfolio from the recommendations of the Ministry of Health for the treatment of COVID-19 - and ensure uninterrupted supplies to different regions of Russia, "said Rustem Muratov, President of Synthesis OJSC. - As a result, in the first half of 2020, the company's sales in the hospital segment doubled (+ 104%) year-on-year in monetary terms. "

Secondary sales in the retail segment grew by 34.2% yoy. The leaders in sales were the analgesic Ibuprofen and the anti-inflammatory drug Diclofenac.

History

2024: Starting the filling line for the dispersion of sterile antibiotics into vials

Binnopharm Group continues to modernize the production site of Synthesis PJSC in Kurgan, which is the largest manufacturer of antibiotics in Russia. The company has launched a filling line for the dispersion of sterile antibiotics into vials, which will increase the volume of production of these forms of drugs by 30%.

Antibiotics, especially in injectable forms, remain extremely popular, in this regard, we decided to increase their production. The launched line is one of the most modern in the country and shows high power. I am sure that its launch will help consolidate our leadership positions, both in Russia and in foreign markets, said Rustem Muratov, CEO of Binnopharm Group.

Earlier, PJSC Sintez completed the modernization of lines for the production of active pharmaceutical substances (APIs), the priority of which is to provide its own APIs for the production of finished forms of antibiotics, including in injectable forms.

2023

Summer internship by 140 students

One hundred and sixty students completed internships and practices in the summer of 2023 at five Binnopharm Group production sites in different regions of Russia. Of these, one hundred and forty people worked at the largest of the five factories of the company - PJSC Sintez in Kurgan. Among those who completed an internship at Synthesis are students of Kurgan State University, Tyumen State University, Yekaterinburg State University, as well as Kurgan Industrial and Pharmaceutical Technical Schools.

At Synth, the guys mainly worked in the laying and packaging area in the 5th, 6th, 7th workshops. Future laboratory chemists trained in the quality service. Future pharmacist technologists also worked in the 5th, 6th, 7th workshops, but in the positions of technologists, shift foremen and site managers. Thus, students not only received their first salaries and skills of the profession, but also helped one of the largest enterprises in the country, a manufacturer of antibacterial drugs, which is actively developing and increasing production capacity.

"This year we have really broken all records for the number of students working in the summer in our productions. It is especially pleasant that the guys are very talented and thoughtful, interested in developing in their profession. We even additionally awarded some for the results achieved. We will definitely continue to accompany students, make an additional special scholarship program for them and, we hope that after graduation, they will begin their careers at Synth and other Binnopharm Group production sites. Working with future specialists best reflects one of the basic principles of our company - to develop human capital, "said Tatyana Fedchenko, Director of Personnel and Organizational Development at Binnopharm Group.

Fine in the case of an explosion in the workshop

An employee of the antibiotic manufacturer Sintez was fined 200 thousand rubles in the case of an explosion in the workshop. This decision of the Kurgan City Court on March 29, 2023 was reported in the regional prosecutor's office. Read more here.

Infusion Solution Line Launch Plan

On February 28, 2023, Binnopharm Group announced that it was continuing to modernize its production site, Synthesis PJSC in Kurgan, this would strengthen the company's position in the production of antibiotics and strengthen its competence in the production of injectable drugs. The company will install a line producing infusion solutions included in the list of vital and essential drugs.

Along with the existing equipment that pours infusion solutions into glass containers, the installed line will be poured into plastic vials, which will make it possible to produce other names of drugs, including the antimicrobial agent Linezolid (an antibiotic of the oxazolidinone group) and the local long-acting anesthetic Ropivabin (ropivacaine).

Work on the installation of equipment will be completed by the end of March 2023. Taking into account the organizational measures and the necessary registration procedures, the release of finished products is planned to begin in the first quarter of 2024.

Previously, the line of infusion solutions was located at the sites of the production pharmaceutical company Alium (part of Binnopharm Group) in Angelovo near Moscow. In the future, PFC Alium will become part of the Binnopharm Group, a single research and development center, which is planned to open in early summer 2023.

The enterprise will also create a site using high-tech equipment, where sterile active pharmaceutical substances intended for the release of finished dosage forms will be produced by freeze-drying.

Thanks to the introduction of the line, the production of eye drops will be increased by 1.5 times, including due to the localization of the antibacterial drug Ciprolet, which was acquired by Binnopharm Group as part of the signing of an agreement with the international pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE).

Maintaining strong growth is a key part of our strategy. We strive to increase our share not only in the Russian market, but also in other countries. By modernizing Synthesis, we are creating additional jobs in the region, as well as a platform for international cooperation, in particular, to promote our drugs in China as part of future Binnopharm Group projects, said Rustem Muratov, CEO of Binnopharm Group.

Earlier, Binnopharm Group announced that it plans to invest 3 billion rubles in the modernization of the Sintez pharmaceutical plant in Kurgan. The company plans to reconstruct workshops, update the fleet of equipment and build a warehouse complex.

2022

Increased production of beta-lactam antibiotics

In 2022, PJSC Sintez (part of Binnopharm Group) increased the production of beta-lactam antibiotics, including Sultasin - an increase of 33% year-on-year, Ampicillin - an increase of 69%, Ceftazidim - an increase of 24%, as well as Vancomycin - an increase of 33%. Binnopharm Group announced this on December 27, 2022. Read more here.

An explosion occurred at a plant in Russia

At the end of April 2022, an explosion occurred at the plant of one of the largest pharmaceutical companies in Russia, Sintez. One person was injured, he was taken to the first city hospital, where they provide urgent medical care.

According to RBC in the press service of the enterprise, the explosion occurred on the territory of workshop No. 4 after the end of the working day, as a result of the incident, part of the enclosing structure of the production building was destroyed. The plant assured that there is no risk of escalation of the situation, the incident does not pose a danger to environmental safety.

In "Synthesis" they said that at the time of the incident the working day was over, and most of the employees had already left the factory.

Шаблон:Quote 'A specially created commission is conducting an internal investigation, the reasons for what happened are being established, - said the press service of "Synthesis." Boris Zhorov, executive director of Synthesis PJSC, said that the company monitors the condition of the victim and takes on all the costs associated with treatment. His condition was not reported by May 3, 2022. Also, the causes of the explosion are not named.

After the explosion, a fire broke out at the enterprise, the fire was localized on an area of ​ ​ 200 square meters. m, a representative of emergency services told RIA Novosti.

According to to data Telegram the Baza channel, as a result of the explosion, the third floor of one of the production buildings was destroyed, previously, the cause of the explosion is considered a violation of the technological process.

The Investigation Department of the Investigative Committee of the Russian Federation for the Kurgan Region opened a criminal case under the article on violation of labor protection rules, which, through negligence, caused grievous harm to human health (part 1 of article 143 of the Criminal Code). The ministry said that "as a result of cotton, which caused the destruction of the upper floor of one of the production buildings"^[1] factory of^[2]

The start of the creation of a pharmaceutical warehouse complex in Kurgan for 2 billion rubles

On February 4, 2022, the pharmaceutical company Binnopharm Group (part of the AFK Sistema Group) announced to Zdrav.Expert that it had begun designing a modern pharmaceutical warehouse complex at the Sintez plant in Kurgan, where the stock of raw materials, materials, as well as finished products will be concentrated. Investments in the project will amount to about 2 billion rubles.

As the general director of Binnopharm Group Rustem Muratov said, the creation of a large, modern warehouse licensed according to GMP/GDP standards with effective internal logistics is the first stage of a large-scale investment project for the development of production in Kurgan. According to the holding's estimates, an increase in warehouse capacity by more than 2 times will give the group an additional opportunity to expand and increase production volumes.

"The strategic goal of the project for the development of the Kurgan production site is to increase labor productivity and the efficiency of using production facilities, as well as focus on those areas where Synthesis is strong historically: the production of medicines and, in particular, antibacterial drugs," added Rustem Muratov.

The warehouse complex is designed using advanced technologies. The territory of the complex is planned to be divided into five zones with different temperature regimes. Also, a temporary storage warehouse is organized here, where customs clearance of goods will take place. This is expected to significantly optimize the supply chain of imported raw materials to the plant.

2021

Sistema Telecom Assets transferred 32.4% of the share capital of Sintez to Binnopharm Group

On May 12, 2021, Binnopharm Group informed Zdrav.Expert that a 100% subsidiary of Sistema PJSC Sistema LLC Sistema Telecom Assets contributed its stake in 32.4% of the authorized capital of Sintez OJSC to the authorized capital of Binnopharm Group LLC. As a result of the transaction, Binnopharm Group increased its stake in OJSC Sintez to 88.6%.

As a result, Sistema's effective stake in Binnopharm Group, together with Sistema's VTB financial pharmaceutical business development partner, amounted to 86.5%; a consortium of investors consisting of, - Russian Direct Investment Fund (RDIF) RussianChinese an investment fund created by RDIF and, China Investment Corporation as well as the largest Middle Eastern funds - 12.5%; the remaining 1% is owned by a minority shareholder - an individual.

AFK Sistema bought from Natsimbio a stake in the pharmaceutical company Sintez

At the end of March 2021, Rostec"" announced the sale of its stake in Synthesis. We are talking about 32.4% of the authorized capital of a pharmaceutical company, which it acquired AFK Sistema through its subsidiary Telecom System Assets. The seller as part of the transaction was the holding "" included in Rostec. Natsimbio The financial component of the agreement has not been disclosed.

The increase in the share in the authorized capital of OJSC Sintez is in line with the strategy of AFK Sistema to increase its presence in the pharmaceutical sector and build one of the industry leaders on the basis of Binnopharm Group. At the same time, we continue to cooperate with Natsimbio and the state corporation Rostec on a number of pharmaceutical projects, including the production of a vaccine against hepatitis B Regevak V, - explained the president of AFK Sistema Vladimir Chirakhov, whose words are quoted by the press service of Rostec.

According to Natsimbio CEO Andrei Zagorski, the Rostec structure will focus on the development of biopharmaceutical enterprises included in the holding's management loop to bring modern Russian-made immunobiological drugs of the full cycle to the market.

Sintez is part of the Binnopharm Group pharmaceutical holding, which also combines four production sites (JSC "" in Alium the Serpukhov district, Moscow region JSC "Binnopharm" in Zelenograd and Krasnogorsk, CJSC "" in Biolump Stavropol).

The effective share of AFK Sistema together with VTB in Binnopharm Group is 79%, and the consortium of investors is 15.8%. The remaining 5.2% of the shares are distributed among minority shareholders - individuals. The effective share of Binnopharm Group in OJSC Sintez is 56.2% (by the end of March 2021). Sintez produces more than 300 types of drugs and medical products, of which about 30% is produced from its own substances.^[3]

Antibiotic Production Site Upgrade Plans

On February 12, 2021 pharmaceutical , the holding "" Binnopharm Group announced plans to modernize the antibiotic production site at the Synthesis plant in. Barrow Plans to update production were presented Minister of Industry and Trade of the Russian Federation Denis Manturov during his visit to the Kurgan site "Binnopharm Group."

Throughout 2020, pharmaceutical factories have been at the forefront of the fight against COVID-19, providing the health care system with the necessary volume of drugs for the prevention and treatment of coronavirus infection. Many factories have switched to round-the-clock operation, having increased the production of the required drugs tenfold, and the Binnopharm Group factories are among them. Until now, these enterprises live in busy mode, working in several shifts. Therefore, we welcome initiatives to modernize and update production, especially in terms of the production of socially significant drugs, - said the Minister of Industry and Trade of the Russian Federation Denis Manturov.

In 2020, the Binnopharm Group Kurgan plant increased the production of antibiotics and other drugs recommended for the treatment of COVID-19 by 44%. This became possible thanks, among other things, to the creation of an additional site for the production of substances for antibiotics (investments in the project - more than 320 million rubles). Also in April 2020, Sintez received a preferential loan from the RF Industrial Development Fund in the amount of 500 million rubles to create stocks of raw materials and increase the production of drugs for the treatment of viral infections.

The plans for 2021 include the continuation of a large-scale modernization of the plant with a special focus on improving and expanding the production of antibiotics, said Rustem Muratov, General Director of the Binnopharm Group holding.

Kurgan plant "Binnopharm Group" - "Synthesis" - as of February 2021 produces 300 drugs, 84 of which are included in the list of vital and essential drugs, 14 - in the recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19.

2020

Inclusion in Binopharm Group Holding

On October 30, 2020, Sintez informed Zdrav.Expert that the pharmaceutical holding, which unites the portfolio companies of AFK Sistema - Alium JSC (includes Binnopharm JSC) and Sintez OJSC (includes Biocom CJSC), announced strategic directions of development. The holding will operate under the Binnopharm Group brand. Read more here.

Production of about 300 million packages of medicines per year

As of August 2020, Sintez produces about 300 million packages of medicines per year. At the same time, the assortment of the plant has more than 300 items of drugs and medical products. More than 84 drugs are on the VED list. More than 35% of products are produced from their own pharmaceutical substances.

Transfer of asset management to Alium Group

On July 20, 2020, PJSC AFK Sistema announced the creation of the Alium Group company, which transferred stakes in the Corporation in pharmaceutical companies Sintez OJSC (owned by Biok CJSC) and Alium JSC (combines the assets of FP Obolenskoye JSC and Binnopharm JSC under the Alium brand). Read more here.

AFK Sistema became the owner of 56.2% of Sintez

On May 26, 2020, AFK Sistema announced an increase in its share in the Kurgan Society of Medicines and Products Sintez from 46.51% to 56.2%. As the corporation told Vedomosti, the shares were bought from minority shareholders. Which ones - the representative did not say.

The transaction was carried out by Sinocom Investments Limited, a holding company for AFK Sistema. She bought ordinary shares at a price of 62.2 thousand rubles apiece and preferred for 5.3 thousand rubles.

Sinocom acquired 13,696 common shares and 20,577 preferred shares of OAO Sintez . The total cost of repurchasing securities of one of the largest drug manufacturers in Russia, including antibiotics, amounted to 959.7 million rubles.

AFK Sistema is considering the possibility of combining its packages in pharmaceutical assets into one holding, a representative of the corporation told Vedomosti.

According to sources of Vademecum, AFK's pharmaceutical assets can be transferred under a single management under the leadership of Sergey Klykov, General Director of Farm Center JSC. AFK Sistema, in addition to Synthesis, owns Biocom and other pharmaceutical plants that are part of the Alium holding.

First, AFK Sistema acquired through Sinocom 46.5% of the shares of the Sintez plant for 11.8 billion rubles. As part of this transaction, the corporation sent its own funds and funds of a "financial partner" represented by VTB to acquire 250 million rubles.

By May 26, 2020, Sintez produces more than 300 names of drugs and medical products, of which about 30% is produced from its own substances. His portfolio includes antibiotics, pulmonological drugs, drugs for the treatment of the musculoskeletal system, etc. 32.39% of Synthesis remain with Natsimbio. The remaining share is owned by individuals.^[4]

Appointment of Rustem Muratov as President of OAO Sintez

On April 20, 2020, by the decision of the Board of Directors of OAO Sintez (part of AFK Sistema, also the shareholder is OA Natsimbio), personnel changes were carried out in the company.

Sergey Klykov, General Director of ZAO Pharm-Center, the management organization of OAO Sintez, transferred a number of powers for the operational management of OAO Sintez to the President (a previously defunct unit) in order to focus on strategic tasks. In addition to strategic development issues, CJSC Pharm Center will resolve issues of corporate governance, development of corporate policies and procedures.

Rustem Muratov, who previously served as director of commerce and marketing at the company, took over as president of Sintez OJSC. In this capacity, he is responsible for fulfilling operational tasks, fulfilling budget indicators, developing the product portfolio and R & D.

We decided to reform the management system and divide a number of operational and strategic tasks, which will bring the business to the next level, - said Sergey Klykov, General Director of Farm Center CJSC, management company of Synthesis OJSC and Biokom CJSC.

The commercial direction of OJSC Sintez was headed by Ekaterina Slavgorodskaya, who previously held the position of Head of the Sales and Promotion Department.

Inclusion in the list of backbone organizations in Russia

At the end of March 2020, the Government Commission for Improving the Sustainability of the Russian Economy approved a list of 646 strategic organizations, the stability of which, in the context of the collapse of oil prices and the coronavirus pandemic, was named a priority for the country.    "Synthesis" was included in the list of system-forming (No. 85), as it is one of the largest drug manufacturers in Russia. The company's portfolio includes more than 300 products, 84 of them are included in the VED list. In 2019, the company produced more than 300 million packages of drugs and medical devices. The scale can be easily imagined: this is conditionally 2 packages for each person in Russia, "explained Sergei Klykov, General Director of Synthesis OJSC on April 2, 2020 .

The plant is the leading manufacturer of antibiotics cephalosparin and penicillin rows in Russia. Most of the antibacterial drugs are produced in the city of Kurgan in a full cycle - from the stage of production of substances. 

2019

Revenue growth of 24%

On March 27 Kurgan pharmaceutical , 2020, the Sintez plant reported Zdrav.Expert financial results under RAS for 2019. The company's revenue increased by 24% year-on-year to 10.6 billion, rubles EBITDA and increased by 16% year-on-year to 1.6 billion rubles.

In 2019, Sintez produced more than 280 million packages of finished products, which is 22% more than in 2018. The bulk of production in physical terms was in infusion solutions, tablets, as well as in the segment of ointments and gels. As part of the import substitution program and the plant modernization plan ("Investment Program - 2019"), Sintez expanded the production of finished dosage forms of cephalosporin and penicillin antibiotics, launched additional capacities for the production of ointments and gels (doubling the volume of products), and also launched workshops for the production of pharmaceutical substances. In 2019, the plant received a registration certificate and became the only manufacturer of Diclofenac Sodium substance in Russia; as of March 2020, the plant's production facilities allow producing about 9 tons per year.

Compared to 2018, the company's secondary sales in the retail segment increased by 42%, which ensured an increase in the rating of retail manufacturers by 11 points (Alpharm data). Also, "Synthesis" was included in the TOP-15 of manufacturers of the rating in physical terms. The leaders in sales in the retail segment were: Diclofenac gel, whose annual sales exceeded 1 billion rubles; Ibuprofen (+ 62% in monetary terms); "Angiorus" (+ 134% in monetary terms); Colds (+ 163% in monetary terms) and Oflomelid (+ 53% in monetary terms).

We systematically approach the development of "Synthesis." The upgrade of equipment, expansion of capacities and development of the production of pharmaceutical substances ensure the possibility of increasing the production of key products of the enterprise in a full cycle in Russia. This is extremely important in the context of ensuring the national security of the country. At the same time, we are actively developing retail sales and systematically increasing volumes in the hospital segment, where the growth was 14% in monetary terms. According to the results of 2019, Sintez remains the country's leading manufacturer of antibiotics and other prescription drugs, and is also one of the fastest growing companies in the retail market, says Sergey Klykov, General Director of Synthesis OJSC

According to the results of 2019, the company's exports increased by 44% in monetary terms and amounted to 14% of revenue. The countries with the largest growth in monetary terms: Uzbekistan (+ 175%), Kyrgyzstan (+ 23%) and Kazakhstan (+ 15%). The leaders in export sales were: injectable antibacterial drugs (cephalosporins, penicillins), capsules and infusion solutions.

In August 2019, the public Russian diversified holding company PJSC AFK Sistema became a shareholder of Sintez OJSC, the other major shareholder is Natsimbio JSC of the State Corporation Rostec.

Sales of Diclofenac reached 1 billion rubles

On January 28, 2020, Sintez reported that according to the results of 2019, sales of the anti-inflammatory drug Diclofenac doubled and reached 1 billion rubles. At the same time, the market share of the drug in its category in physical terms exceeded 43% (AlphaRM data). Thus, the Diclofenac gel became the first bestseller in the portfolio of drugs of OJSC Sintez. Read more here.

AFK Sistema closed the acquisition of Sintez and Biocom

Marathon Group and AFK Sistema closed the acquisition of pharmaceutical companies Sintez and Biocom. This was announced on August 8, 2019 by the Marathon Group. Read more here.

AFK Sistema will acquire Sintez and Biocom from Marathon Group

AFK Sistema, a public Russian diversified holding company, and investment company Marathon Group on June 7, 2019 announced the signing of binding documentation on the acquisition of shares in two pharmaceutical companies - Kurgan Society of Medicines and Products Sintez and Biocom. The closing of the transaction is expected within three months, after receiving the approval of the FAS and fulfilling other preventive conditions. The transaction price is not disclosed, but, as specified, depends on a number of conditions agreed by the parties. Read more here.

Investing 3.5 billion rubles in the modernization of production

On February 14, 2019, Acting governor Kurganskaya Region Vadim Shumkov, Deputy General Director of Natsimbio JSC Philip Pershkov and Head of Joint Stock Kurgan Society of Medicines and Products Sintez Sergey Klykov signed an agreement on the joint development of the plant and cooperation in the socio-economic sphere.

The parties agreed on cooperation in the implementation of investment activities in the field of healthcare in the Kurgan region, including the development of the production of drugs and medical devices, import substitution, the development of new dosage forms, scientific research, etc.

As part of the agreement, OJSC Sintez is starting to implement a large-scale investment program: by the end of 2020, the plant plans to invest 3.5 billion rubles of its own funds in the modernization of production, of which 1.4 billion in 2019.

We intend to maintain the leadership of Synthesis in the antibiotic market, so most of the funds will be invested in equipping the workshops for the production of semi-synthetic antibiotics of the latest generation, - said Sergey Klykov. - Another major investment will be the launch of a new line for the manufacture of gels, which is gaining popularity among consumers of the form of drugs. As a result, we expect production growth in physical terms by at least a quarter this year.

According to the head of Synthesis, a significant modernization is also waiting for the enterprise's IT system, which, in particular, is associated with the introduction of a product labeling system. In addition, work will continue on the development of the energy complex, which, if necessary, will ensure the autonomy of the supply of thermal energy to the enterprise. Some of the funds will be used to equip the laboratories of the quality control department.

The Agreement signed in Sochi also implies cooperation between Synthesis OJSC with the regional department of education and science and the largest university in the Trans-Urals - Kurgan State University.

According to the Acting Governor of the Kurgan Region Vadim Shumkov, the regional leadership is interested in modernizing Synthesis, one of the largest employers in the region:

The development of our enterprises, and, in particular, the plant at which more than 3 thousand people work, is a guarantee of the stability of the socio-economic situation in the region. We welcome the plans of Synthesis to train its own personnel and create jobs in Kurgan and are confident that the joint efforts of the plant, the regional government and the university will achieve the goals set in a short time.

It is planned that from 2019 Sintez will develop training and retraining programs for personnel required by the plant in cooperation with the relevant departments of KSU, and the university will provide target places for students who, after studying, will join the team of Sintez OJSC.

2018

Revenue 8.5 billion rubles (+ 16%)

At the end of 2018, the plant's revenue exceeded 8.5 billion rubles (an increase of 16% by 2017), Sintez was included in the TOP-3 of pharmaceutical enterprises in Russia, which showed the highest growth rates in the retail segment. According to Sergei Klykov, head of Synthesis OJSC, such results were achieved largely due to the phased modernization of production and the reorganization of key departments of the enterprise, as well as the adjustment of the plant's marketing strategy. As a result, such drugs as Diclofenac, Sultasin, Ceftriaxone and Rinorus were in the greatest demand among consumers in retail. Last year, a new venotonizing agent Angiorus was launched on the market, the sales of which by the end of December exceeded 270 thousand packages for a total amount of over 141 million rubles. The increase in sales of "Synthesis" in the hospital sector amounted to about 20%.

"The largest volume of production and, accordingly, sales fell on the pharmacological group" powders for injection, "followed by ointments and gels," says Sergey Klykov.

According to 2018 data, Sintez OJSC is one of the largest enterprises in the Kurgan region, providing 7% of the region's GRP (data for August 2018).

Start-up of lyophilic and spray drying laboratory complex

On August 2, 2018, Sintez (part of Marathon Pharma and Natsimbio) announced its investment in the development of its own R&D center as part of solving the strategic task of increasing the production of drugs from its own substances. So, in August, a laboratory complex of freeze-drying and spray drying was launched, designed to develop technologies for the production of domestic substances.

The complex allows you to experiment even with 1 gram of substance in order to create compounds and optimize the processes of production of substances. The laboratory, in particular, is working on the effectiveness of the technology for creating substances for a number of antibiotics - ampicillin, cefazolin, sulbactam, amikacin, kanamycin.

Thanks to the development of its own R&D center, Sintez plans to significantly expand the portfolio of plant drugs produced in a full cycle and double the share of such drugs by 2025.

The laboratory is a reduced copy of the Synthesis workshop for the production of substances, the capacity of which is tens of tons of substances per year. Earlier, the development of the new technological process in industrial conditions took from six to twelve months, laboratory installations will reduce the duration of the launch period by three to four times and in a short time increase the production of substances - both for the production of their own drugs and for sale to external counterparties, according to the company.

As of August 2018, Sintez already supplies a number of proprietary substances to the market, for example, Chondroitin sulfate, used for the production of drugs for the treatment of the musculoskeletal system.

In general, the laboratory complex is the seventh in the Central Laboratory "Synthesis," which employs more than 50 people, and which, according to 2018, also includes a laboratory of ready-made dosage forms, a laboratory of biologically active substances and semi-synthetic antibiotics, microbiological sector, etc.

Leadership in the volume of antibiotic production in Russia

The Synthesis Pharmaceutical Plant (Kurgan), a joint venture of the state corporation Rostec and Marathon Group, at the end of 2017 produced over 32 million packages of antibacterial agents, or 23% of the total number of antibiotics produced in Russia. According to the industry analytical company Alpharm, Sintez leads the market both in kind (amount of products produced) and in monetary terms.

The SP portfolio includes more than 50 antibacterial drugs in various dosage forms (solid, liquid solutions, ointments and drops). Production of 30% of products is the production of a full cycle from its own substances, for example, cephalosporins, penicillins of all spectra of action, fluoroquinolones and others.

For "Synthesis," antibiotics are a key product, more than 50% of the company's sales are antibacterial drugs, which the plant produces historically: back in the early 60s, one of the first in the USSR to establish the production of substances for antibiotics, and then began to produce finished dosage forms, - said Andrei Zagorski, General Director of Natsimbio (part of Rostec and Marathon Group). - In 2018-2020, as part of the import substitution program, Sintez plans to launch new drugs, which will allow the company to increase its share in the Russian-made antibiotic market.

In total, Sintez produces 73 names of vital and essential drugs.

Direct marketing contracts with pharmacy associations "ProPharmacy," "ASNA" and "Constellation"

In March 2018, the Kurgan Joint Stock Company of Medical Products and Products Sintez entered into direct marketing contracts with the pharmacy associations ProPharmacy, ASNA and Sozvezdiye. This cooperation is another step in the implementation of the strategy of Synthesis OJSC, implemented since the end of 2016 by a new management team and aimed, in particular, at a multiple increase in retail sales of the plant's drugs.

According to the agreements reached with pharmacy associations, 50 prescription and over-the-counter drugs manufactured by OJSC Sintez - high-quality domestic generics - will now be presented in more than eight thousand pharmacies throughout the country. The list of products supplied under direct marketing contracts will include, in particular, the flagship drugs of the plant - the anti-inflammatory drug of external use "Diclofenac-gel," the nasal spray "Rinorus" and the anti-vascular agent "Colds."

"Many

Synthesis drugs have good potential, especially against the background of the steadily growing consumer demand for high-quality generics in recent years," says Andrey Chicherin, director of commerce and marketing at Synthesis OJSC. - Previously, the range of our drugs presented in pharmacies, by tradition, was determined by distributors - with not always obvious effectiveness. In direct cooperation with pharmacy associations and with favorable market conditions, we expect to increase retail sales of individual drugs many times over. "

2017

Revenue growth of 7%

Compared to 2016, the company's revenue increased by 7.6% to 7.26 billion rubles. Net profit increased 1.5 times and amounted to 1.06 billion rubles. The company has produced about 300 million units of products.

In 2017, OAO Sintez focused on optimizing its commercial structure. Three key areas were identified: an increase in retail sales, the development of the public procurement segment, as well as an increase in exports. Sales of over-the-counter drugs grew by 22% in 2017. Among the flagships are products such as the Rhinorus nasal spray, the anti-inflammatory drug Diclofenac-gel, the cardiological drug Acecardol, and the anti-vascular agent Colds. In the public procurement segment, a list of key INNs for which the plant is actively operating in the market was determined. In terms of exports, OAO Sintez expanded contracts in Kazakhstan and agreed on direct supplies to Uzbekistan. As a result, export revenue grew by 6% in 2017.

"In 2016, the team began to reform the enterprise - a new management and control system was introduced. The year turned out to be a breakthrough - revenue grew by 1 billion rubles, and net profit doubled. In 2017, we continued to work on optimizing our business processes. Profit growth was made possible by the transition to direct contracts with suppliers of substances. Today, about 90% of imported raw materials are purchased from foreign producers, and not through intermediaries. As a result, revenue continued to grow steadily - 7.6% in 2017, and net profit increased 1.5 times, "says Igor Krylov, Managing Partner of Marathon Pharma

.

More than 50% of the Synthesis portfolio - VEDs

As of October 2017, the assortment of the plant has more than 300 items of drugs and medical devices. At the same time, more than 50% of the Synthesis portfolio is made up of drugs from the VED list. Sintez is one of the largest enterprises in the Kurgan region, providing 7% of the region's GRP.

As part of Marathon Pharma

Since 2017, Sintez OJSC has been part of Marathon Pharma, a sub-holding of Marathon Group.

Notes